Literature DB >> 5637779

L-Dopa for Parkinsonism.

G C Cotzias.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5637779     DOI： 10.1056/nejm196803142781127

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  27 in total

1.  Parkinson and his disease revisited.

Authors:  D G James; R Hierons
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

2.  Multisystem Lewy body disease and the other parkinsonian disorders.

Authors:  J William Langston; Birgitt Schüle; Linda Rees; R Jeremy Nichols; Carrolee Barlow
Journal:  Nat Genet       Date:  2015-12       Impact factor: 38.330

3.  Dr Lewis Kitchener Dahl, the Dahl rats, and the "inconvenient truth" about the genetics of hypertension.

Authors:  Bina Joe
Journal:  Hypertension       Date:  2015-02-02       Impact factor: 10.190

4.  Behavioral impairments and serotonin reductions in rats after chronic L-dopa.

Authors:  Branden J Stansley; Bryan K Yamamoto
Journal:  Psychopharmacology (Berl)       Date:  2015-06-03       Impact factor: 4.530

5.  Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.

Authors:  Guoxiang Liu; Carmelo Sgobio; Xinglong Gu; Lixin Sun; Xian Lin; Jia Yu; Loukia Parisiadou; Chengsong Xie; Namratha Sastry; Jinhui Ding; Kelly M Lohr; Gary W Miller; Yolanda Mateo; David M Lovinger; Huaibin Cai
Journal:  Hum Mol Genet       Date:  2015-06-29       Impact factor: 6.150

Review 6.  MicroRNAs in Parkinson's disease.

Authors:  Maged M Harraz; Ted M Dawson; Valina L Dawson
Journal:  J Chem Neuroanat       Date:  2011-02-02       Impact factor: 3.052

Review 7.  When should levodopa therapy be initiated in patients with Parkinson's disease?

Authors:  Irene A C Halkias; Ihtsham Haq; Zhigao Huang; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

8.  Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha.

Authors:  Feifei Wang; Takao Yasuhara; Tetsuro Shingo; Masahiro Kameda; Naoki Tajiri; Wen Ji Yuan; Akihiko Kondo; Tomohito Kadota; Tanefumi Baba; Judith Thomas Tayra; Yoichiro Kikuchi; Yasuyuki Miyoshi; Isao Date
Journal:  BMC Neurosci       Date:  2010-04-26       Impact factor: 3.288

9.  Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease.

Authors:  Anna Nilsson; Maria Fälth; Xiaoqun Zhang; Kim Kultima; Karl Sköld; Per Svenningsson; Per E Andrén
Journal:  Mol Cell Proteomics       Date:  2009-01-08       Impact factor: 5.911

10.  A controlled study of L-DOPA in Parkinson's disease.

Authors:  W W Hofmann; R L Ryan
Journal:  Calif Med       Date:  1970-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.